SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version: 2.4  Revision Date: 28.09.2020  SDS Number: 2403215-00007  Date of last issue: 23.03.2020
Date of first issue: 01.02.2018

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ertugliflozin (< 5%) / Sitagliptin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: MSD
Shotton Lane
NE23 3JU Cramlington NU - Great Britain

Telephone: 44 1 670 59 30 00
Telefax: 908-735-1496
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Skin irritation, Category 2  H315: Causes skin irritation.
Serious eye damage, Category 1  H318: Causes serious eye damage.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:
Signal word: Danger

Hazard statements:
H315  Causes skin irritation.
H318  Causes serious eye damage.

Precautionary statements:
Prevention:
P264  Wash skin thoroughly after handling.
P280  Wear protective gloves/ eye protection/ face protection.
Response:
P305 + P351 + P338 + P310  IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
P332 + P313  If skin irritation occurs: Get medical advice/attention.
P362 + P364  Take off contaminated clothing and wash it before reuse.

Hazardous components which must be listed on the label:
Ertugliflozin

2.3 Other hazards
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td></td>
<td></td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 STOT RE 2; H373 (Kidney, Stomach, Prostate)</td>
<td>&gt;= 3 - &lt; 5</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks:
- Causes skin irritation.
- Causes serious eye damage.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment:
- Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides
- Oxides of phosphorus

5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.
Ertugliflozin (< 5%) / Sitagliptin Formulation

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow.
Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Hand protection**: Material - Chemical-resistant gloves; Remarks - Consider double gloving.

- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143

- **Filter type**: Particulates type (P)

**SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

- **Appearance**: powder
- **Colour**: No data available
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: Not applicable
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>28.09.2020</td>
<td>2403215-00007</td>
<td>23.03.2020</td>
<td>01.02.2018</td>
</tr>
</tbody>
</table>

flammability limit

Vapour pressure : Not applicable
Relative vapour density : Not applicable
Relative density : No data available
Density : No data available

Solubility(ies)
  Water solubility : No data available
  Partition coefficient: n-octanol/water : Not applicable
  Auto-ignition temperature : No data available
  Decomposition temperature : No data available

Viscosity
  Viscosity, kinematic : Not applicable

Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
                    : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
                     : Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents
10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:
Sitagliptin:
Acute oral toxicity: LD50 (Rat): > 3.000 mg/kg
LD50 (Mouse): 3.000 mg/kg

Ertugliflozin:
Acute oral toxicity: LD50 (Rat): 500 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Causes skin irritation.

Components:
Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Ertugliflozin:
Result: Corrosive

Serious eye damage/eye irritation
Causes serious eye damage.

Components:
Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: Irritating to eyes.

Ertugliflozin:
Result: Severe irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Method: OECD Test Guideline 429
Result: Not a skin sensitizer.

Ertugliflozin:
Test Type: Local lymph node assay (LLNA)
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Sitagliptin:
Genotoxicity in vitro: Test Type: Ames test
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Ertugliflozin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue: 23.03.2020</th>
<th>Date of first issue: 01.02.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>28.09.2020</td>
<td>2403215-00007</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Result: negative

### Carcinogenicity
Not classified based on available information.

### Components:

#### Sitagliptin:
- **Species**: Mouse
- **Application Route**: Oral
- **Exposure time**: 2 Years
- **Result**: negative
- **Species**: Rat
- **Application Route**: oral (drinking water)
- **Exposure time**: 2 Years
- **Result**: positive
- **Target Organs**: Liver
- **Remarks**: Significant toxicity observed in testing

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

#### Ertugliflozin:
- **Species**: Mouse
- **Application Route**: Oral
- **Exposure time**: 2 Years
- **Result**: negative
- **Species**: Rat
- **Application Route**: Oral
- **Exposure time**: 2 Years
- **Result**: negative

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

### Reproductive toxicity
Not classified based on available information.

#### Components:

#### Sitagliptin:
- **Effects on fertility**: Test Type: Fertility/early embryonic development
  - **Species**: Rat
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>28.09.2020</td>
<td>2403215-00007</td>
<td>23.03.2020</td>
<td>01.02.2018</td>
</tr>
</tbody>
</table>

Application Route: Oral
Fertility: NOAEL Parent: 1.000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected. No teratogenic effects

Test Type: Embryo-foetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects

Ertugliflozin:
Effects on fertility:
Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL: 250 mg/kg body weight
Remarks: Maternal toxicity observed.
No significant adverse effects were reported

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 200 mg/kg body weight
Remarks: No significant adverse effects were reported

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 250 mg/kg body weight
Remarks: No significant adverse effects were reported

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:
Ertugliflozin:
Exposure routes: Oral
Target Organs: Kidney, Stomach, Prostate
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sitagliptin:
Species: Mouse
NOAEL: 500 mg/kg
LOAEL: 1,000 mg/kg
Application Route: Oral
Exposure time: > 2 yr
Target Organs: Kidney

Species: Rat
NOAEL: 500 mg/kg
LOAEL: 1,000 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Liver, Kidney, Heart, Teeth

Species: Dog
NOAEL: 10 mg/kg
LOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Loss of balance
Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Dog
NOAEL: 2 mg/kg
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 27 Weeks
Target Organs: Skeletal muscle, Central nervous system
Symptoms: Loss of balance
Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Monkey
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Ertugliflozin:
Species: Rat
LOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 30 d
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Species: Rat
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Kidney

Species: Rat
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 180 d
Target Organs: Kidney, Bone, Stomach

Species: Rat
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 90 d
Target Organs: Kidney, Gastrointestinal tract, Prostate

Species: Dog
NOAEL: 150 mg/kg
Application Route: Oral
Exposure time: 270 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Bone
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Sitagliptin:
Inhalation: Symptoms: upper respiratory tract infection, pharyngitis, Headache
Ingestion: Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

Ertugliflozin:
Ingestion: Symptoms: The most common side effects are; Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection
SECTION 12: Ecological information

12.1 Toxicity

**Components:**

**Sitagliptin:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): 60 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 2.2 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
- **Toxicity to microorganisms:** EC50: > 150 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209
- **NOEC:** 150 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
- **Toxicity to fish (Chronic toxicity):** NOEC: 9.2 mg/l
  Exposure time: 33 d
  Species: Pimephales promelas (fathead minnow)
  Method: OECD Test Guideline 210
- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC: 9.8 mg/l
  Exposure time: 21 d
  Species: Daphnia magna (Water flea)
  Method: OECD Test Guideline 211

**Ertugliflozin:**
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 50 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.4  Revision Date: 28.09.2020  SDS Number: 2403215-00007  Date of last issue: 23.03.2020
Date of first issue: 01.02.2018

12.2 Persistence and degradability

Components:

Sitagliptin:
Biodegradability: Result: not rapidly degradable
Biodegradation: 39.7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water: pH: 7
Hydrolysis: 50 % (401 d)
Method: OECD Test Guideline 111

Ertugliflozin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 40.8 %
Exposure time: 28 d

12.3 Bioaccumulative potential

Components:

Sitagliptin:
Partition coefficient: n-octanol/water: log Pow: -0.03

Ertugliflozin:
Partition coefficient: n-octanol/water: log Pow: 2.47
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.4  Revision Date: 28.09.2020  SDS Number: 2403215-00007  Date of last issue: 23.03.2020  Date of first issue: 01.02.2018

12.4 Mobility in soil

**Components:**

**Sitagliptin:**
Distribution among environmental compartments: log Koc: 4,37

**Ertugliflozin:**
Distribution among environmental compartments: log Koc: 2,88

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

<table>
<thead>
<tr>
<th>Product</th>
<th>Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contaminated packaging</td>
<td>Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.</td>
</tr>
</tbody>
</table>

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version: 2.4
Revision Date: 28.09.2020
SDS Number: 2403215-00007
Date of last issue: 23.03.2020
Date of first issue: 01.02.2018

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302: Harmful if swallowed.
H314: Causes severe skin burns and eye damage.
H318: Causes serious eye damage.
H319: Causes serious eye irritation.
H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Eye Dam.: Serious eye damage
Eye Irrit.: Eye irritation
Skin Corr.: Skin corrosion
STOT RE: Specific target organ toxicity - repeated exposure
Ertugliflozin (< 5%) / Sitagliptin Formulation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - Quantitative Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bio-accumulative

Further information


Classification of the mixture: Classification procedure:

Skin Irrit. 2 H315 Calculation method
Eye Dam. 1 H318 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.4  Revision Date: 28.09.2020  SDS Number: 2403215-00007  Date of last issue: 23.03.2020

Date of first issue: 01.02.2018

NO / EN